The consequences of delayed diagnosis and treatment in persons with multiple sclerosis given autologous hematopoietic stem cell transplantation.
María de Lourdes Pastelín-MartínezMoisés Manuel Gallardo-PérezAndrés Gómez-de-LeónJuan Carlos Olivares-GazcaEdgar Jared Hernández-FloresDaniela Sánchez-BonillaMerittzel Montes-RoblesMax Robles-NastaGuillermo Ocaña-RammSilvia Soto-OlveraDavid Gómez-AlmaguerGuillermo J Ruiz-DelgadoGuillermo José Ruiz-ArguellesPublished in: Diagnosis (Berlin, Germany) (2024)
These data indicate that both the pre-transplant progression of the disease and the response to aHSCT were significantly worse in the DD group. An early diagnosis and an early aHSCT intervention are critical for a good prognosis, in terms of lowering and stabilizing the motor disability in MS patients given autografts.
Keyphrases
- multiple sclerosis
- end stage renal disease
- ejection fraction
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- mass spectrometry
- prognostic factors
- white matter
- bone marrow
- acute myeloid leukemia
- stem cells
- electronic health record
- peritoneal dialysis
- machine learning
- ms ms
- cell therapy
- patient reported